Lupus nephritis: Glycogen synthase kinase 3β promotion of renal damage through activation of the NLRP3 inflammasome in lupus-prone mice

Arthritis and Rheumatology

Volumn 67, Issue 4, 2015, Pages 1036-1044

  Zhao, Jijun ^a   Wang, Hongyue ^a   Huang, Yuefang ^a   Zhang, Hui ^a   Wang, Shuang ^a   Gaskin, Felicia ^b   Yang, Niansheng ^a   Fu, Shu Man ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; DOUBLE STRANDED DNA ANTIBODY; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; SMALL INTERFERING RNA; THIADIAZOLIDINONE 8; UNCLASSIFIED DRUG; 4-BENZYL-2-METHYL-1,2,4-THIADIAZOLIDINE-3,5-DIONE; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; THIADIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNE COMPLEX DEPOSITION; IN VITRO STUDY; INCIDENCE; INVESTIGATIVE PROCEDURES; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; KIDNEY; MACROPHAGE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARRIER PROTEINS; CELL LINE; GLYCOGEN SYNTHASE KINASE 3; INFLAMMASOMES; KIDNEY; LUPUS NEPHRITIS; MACROPHAGES; MICE; PROTEINURIA; SIGNAL TRANSDUCTION; THIADIAZOLES;

EID: 84925740094     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38993     Document Type: Article

References (30)

1. Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME,. Lupus nephritis: a critical review. Autoimmun Rev 2012; 12: 174-94.
2. Gunnarsson I, Jonsdottir T,. Rituximab treatment in lupus nephritis: where do we stand? Lupus 2013; 22: 381-9.
3. Markopoulou A, Kyttaris VC,. Small molecules in the treatment of systemic lupus erythematosus. Clin Immunol 2013; 148: 359-68.
4. Takahashi-Yanaga F,. Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol 2013; 86191-9.
5. Martin M, Rehani K, Jope RS, Michalek SM,. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005; 6: 777-84.
6. Graham JA, Fray M, de Haseth S, Lee KM, Lian MM, Chase CM, et al. Suppressive regulatory T cell activity is potentiated by glycogen synthase kinase 3βinhibition. J Biol Chem 2010; 285: 32852-9.
7. Beurel E, Yeh WI, Michalek SM, Harrington LE, Jope RS,. Glycogen synthasekinase-3 is an early determinant in the differentiation of pathogenic Th17 cells. J Immunol 2011; 186: 1391-8.
8. Beurel E, Kaidanovich-Beilin O, Yeh WI, Song L, Palomo V, Michalek SM, et al. Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3. J Immunol 2013; 190: 5000-11.
9. Song YC, Tang SJ, Lee TP, Hung WC, Lin SC, Tsai CY, et al. Reversing interleukin-2 inhibition mediated by anti-double-stranded DNA autoantibody ameliorates glomerulonephritis in MRL-lpr/lpr mice. Arthritis Rheum 2010; 62: 2401-11.
10. Michallet MC, Rota G, Maslowski K, Guarda G,. Innate receptors for adaptive immunity. Curr Opin Microbiol 2013; 16: 296-302.
11. Connolly DJ, O'Neill LA,. New developments in Toll-like receptor targeted therapeutics. Curr Opin Pharmacol 2012; 12: 510-8.
12. Strowig T, Henao-Mejia J, Elinav E, Flavell R,. Inflammasomes in health and disease. Nature 2012; 481: 278-86.
13. Tsai PY, Ka SM, Chang JM, Chen HC, Shui HA, Li CY, et al. Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic Biol Med 2011; 51: 744-54.
14. Zhao J, Zhang H, Huang Y, Wang H, Wang S, Zhao C, et al. Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-κB activation. Int Immunopharmacol 2013; 17: 116-22.
15. 7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/caspase 1 pathway. Arthritis Rheum 2013; 65: 3176-85.
16. Coant N, Simon-Rudler M, Gustot T, Fasseu M, Gandoura S, Ragot K, et al. Glycogen synthase kinase 3 involvement in the excessive proinflammatory response to LPS in patients with decompensated cirrhosis. J Hepatol 2011; 55: 784-93.
17. Siegfried A, Berchtold S, Manncke B, Deuschle E, Reber J, Ott T, et al. IFIT2 is an effector protein of type I IFN-mediated amplification of lipopolysaccharide (LPS)-induced TNF-α secretion and LPS-induced endotoxin shock. J Immunol 2013; 191: 3913-21.
18. Zhang L, Yang N, Wang S, Huang B, Li F, Tan H, et al. Adenosine 2A receptor is protective against renal injury in MRL/lpr mice. Lupus 2011; 20: 667-77.
19. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
20. McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R, et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J 2005; 24: 1571-83.
21. Cohen P, Frame S,. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001; 2: 769-76.
22. Kwon YJ, Yoon CH, Lee SW, Park YB, Lee SK, Park MC,. Inhibition of glycogen synthase kinase-3β suppresses inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes and collagen-induced arthritis. Joint Bone Spine 2014; 81: 240-6.
23. Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S, Wilson CB, McConahey PJ, et al. Spontaneous murine lupus-like syndromes: clinical and immunopathological manifestations in several strains. J Exp Med 1978; 148: 1198-215.
24. Klamer G, Song E, Ko KH, O'Brien TA, Dolnikov A,. Using small molecule GSK3β inhibitors to treat inflammation. Curr Med Chem 2010; 17: 2873-81.
25. Cheng YL, Wang CY, Huang WC, Tsai CC, Chen CL, Shen CF, et al. Staphylococcus aureus induces microglial inflammation via a glycogen synthase kinase 3β-regulated pathway. Infect Immun 2009; 77: 4002-8.
26. Yuskaitis CJ, Jope RS,. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal 2009; 21: 264-73.
27. Shin MS, Kang Y, Lee N, Kim SH, Kang KS, Lazova R, et al. U1-small nuclear ribonucleoprotein activates the NLRP3 inflammasome in human monocytes. J Immunol 2012; 188: 4769-75.
28. Shin MS, Kang Y, Lee N, Wahl ER, Kim SH, Kang KS, et al. Self double-stranded (ds)DNA induces IL-1β production from human monocytes by activating NLRP3 inflammasome in the presence of anti-dsDNA antibodies. J Immunol 2013; 190: 1407-15.
29. Kahlenberg JM, Yalavarthi S, Zhao W, Hodgin JB, Reed TJ, Tsuji NM, et al. An essential role of caspase 1 in the induction of murine lupus and its associated vascular damage. Arthritis Rheumatol 2014; 66: 152-62.
30. Avrahami L, Licht-Murava A, Eisenstein M, Eldar-Finkelman H,. GSK-3 inhibition: achieving moderate efficacy with high selectivity. Biochim Biophys Acta 2013; 1834: 1410-4.